Synapse - Marjorie Zauderer

Search Within

Marjorie G Zauderer

Results (188)

Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion

Meeting Abstract

Krug, L. M.; Zauderer, M. G.; Adusumili, P. S.; McGee, E.; Sepkowitz, K.; Klang, M.; Yu, Y. A.; Scigalla, P.; Rusch, V. W.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Assessing the performance of Watson for oncology, a decision support system, using actual contemporary clinical cases

Meeting Abstract

Kris, M. G.; Gucalp, A.; Epstein, A. S.; Seidman, A. D.; Fu, J.; Keesing, J.; Caroline, A.; Megerian, M.; Eggebraaten, T.; DeLima, R.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Electronic medical record as a research tool: Virtual clinical trial comparing pemetrexed and gemcitabine, both given with cisplatin, in patients with lung adenocarcinomas

Meeting Abstract

Grigorenko, A.; May, P.; Kastango, N.; Thaler, H. T.; Wagner, I.; Caroline, A.; Kris, M. G.; Zauderer, M. G.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Steps in developing Watson for Oncology, a decision support system to assist physicians choosing first-line metastatic breast cancer (MBC) therapies: Improved performance with machine learning

Meeting Abstract

Fu, J.; Gucalp, A.; Zauderer, M. G.; Epstein, A. S.; Kris, M. G.; Keesing, J.; Caroline, A.; Megerian, M.; Eggebraaten, T.; DeLima, R.; more...
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

Confirmation of high prevalence of BAP1 inactivation in mesothelioma

Meeting Abstract

Cercek, A.; Zauderer, M. G.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Nash, G. M.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
Journal of Clinical Oncology (2015)

Fulltext@MSK | Save

GDC-0980, a dual PI3K/mTOR inhibitor, selectively inhibits NF2 mutant malignant mesothelioma (MM) cells and inhibits TOR signaling without activating Akt or ERK

Meeting Abstract

Zauderer, M. G.; Moulik, K.; Cooper, J.; Krug, L. M.; Giancotti, F.
Molecular Cancer Therapeutics (2015)

Fulltext@MSK | Save

Piloting IBM Watson Oncology within Memorial Sloan Kettering's regional network

Meeting Abstract

Zauderer, M. G.; Gucalp, A.; Epstein, A. S.; Seidman, A. D.; Caroline, A.; Granovsky, S.; Fu, J.; Keesing, J.; Lewis, S.; Co, H.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

A multicenter phase II toxicity study of lung-sparing intensity modulated radiation therapy (IMRT) for malignant pleural mesothelioma (MPM)

Meeting Abstract

Zauderer, M. G.; Rimner, A.; Rosenzweig, K.; Wu, A. J. C.; Yorke, E.; Sima, C. S.; Bhattacharjee, N.; Patel, Z.; Gomez, D. R.; Tsao, A. S.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

Prevalence of germline BAP1 mutations in patients with malignant mesothelioma (MM)

Meeting Abstract

Hellmann, M. D.; Borsu, L.; Zehir, A.; Cheng, D. T.; Zha, Z.; Siegel, B.; Rohrer, R. W.; Robson, M. E.; Arnold, A. G.; Fleischut, M. H.; more...
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save

COMMAND: A phase II randomized, double-blind, placebo-controlled, multicenter study of defactinib as maintenance therapy in subjects with malignant pleural mesothelioma that has not progressed on at least four cycles of pemetrexed/platinum therapy

Meeting Abstract

Fennell, D. A.; Baas, P.; Kindler, H. L.; Krug, L. M.; Nowak, A.; Zauderer, M.; Gralla, R. J.; Keegan, M.; Horobin, J.
Journal of Clinical Oncology (2014)

Fulltext@MSK | Save